SI1994410T1 - Metode in kompleti za zgodnje odkrivanje raka ali predispozicije zanj - Google Patents

Metode in kompleti za zgodnje odkrivanje raka ali predispozicije zanj

Info

Publication number
SI1994410T1
SI1994410T1 SI200730466T SI200730466T SI1994410T1 SI 1994410 T1 SI1994410 T1 SI 1994410T1 SI 200730466 T SI200730466 T SI 200730466T SI 200730466 T SI200730466 T SI 200730466T SI 1994410 T1 SI1994410 T1 SI 1994410T1
Authority
SI
Slovenia
Prior art keywords
methods
cancer
determining
kits
subject
Prior art date
Application number
SI200730466T
Other languages
English (en)
Slovenian (sl)
Inventor
Nadir Arber
Original Assignee
Medical Res Fund Of Tel Aviv Sourasky Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Fund Of Tel Aviv Sourasky Medical Ct filed Critical Medical Res Fund Of Tel Aviv Sourasky Medical Ct
Publication of SI1994410T1 publication Critical patent/SI1994410T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200730466T 2006-01-31 2007-01-31 Metode in kompleti za zgodnje odkrivanje raka ali predispozicije zanj SI1994410T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31
EP07706065A EP1994410B1 (en) 2006-01-31 2007-01-31 Methods for early detection of cancer
PCT/IL2007/000122 WO2007088537A2 (en) 2006-01-31 2007-01-31 Methods and kits for early detection of cancer or predisposition thereto

Publications (1)

Publication Number Publication Date
SI1994410T1 true SI1994410T1 (sl) 2011-03-31

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730466T SI1994410T1 (sl) 2006-01-31 2007-01-31 Metode in kompleti za zgodnje odkrivanje raka ali predispozicije zanj

Country Status (12)

Country Link
US (1) US9394569B2 (https=)
EP (1) EP1994410B1 (https=)
JP (1) JP5091163B2 (https=)
AT (1) ATE486285T1 (https=)
DE (1) DE602007010108D1 (https=)
DK (1) DK1994410T3 (https=)
ES (1) ES2355388T3 (https=)
IL (1) IL193097A (https=)
PL (1) PL1994410T3 (https=)
PT (1) PT1994410E (https=)
SI (1) SI1994410T1 (https=)
WO (1) WO2007088537A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1994410B1 (en) 2006-01-31 2010-10-27 Medical Research Fund of Tel Aviv Sourasky Medical Center Methods for early detection of cancer
EP2220505B1 (en) * 2007-12-10 2015-10-28 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of diagnosing cancer
US7888035B2 (en) * 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
PT2572193T (pt) * 2010-05-21 2018-01-31 Univ Alberta Métodos para a examinação de cancro colorretal e pólipos colorretais por medição de metabólitos na urina
WO2015050919A1 (en) 2013-10-01 2015-04-09 Life Technologies Corporation Systems and methods for detecting structural variants
WO2018216006A1 (en) 2017-05-21 2018-11-29 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Combination of markers for diagnosing cancer
EP3447154A1 (en) * 2017-08-23 2019-02-27 Instytut Genetyki Sadowej Jolanta Powierska - Czarny Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics
EP3759493A1 (en) * 2018-02-28 2021-01-06 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
EP3888021B1 (en) 2018-11-30 2024-02-21 Caris MPI, Inc. Next-generation molecular profiling
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
CA3163319A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571539A4 (en) * 1991-02-05 1994-06-29 Kamal Bahar Simple test for detecting carcinoembryonic antigen
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
EP1497642A2 (en) 2002-03-19 2005-01-19 Tularik, Inc. Gene amplification in cancer
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
EP1706507A4 (en) * 2003-11-26 2008-02-20 Univ Ohio State Res Found THE RISK AND PROGRESSION OF MULTIPLE SCLEROSIS PREDICTING POLYMORPHS CD24 GENOTYPES
CA2453198A1 (en) * 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
EP1994410B1 (en) 2006-01-31 2010-10-27 Medical Research Fund of Tel Aviv Sourasky Medical Center Methods for early detection of cancer

Also Published As

Publication number Publication date
ATE486285T1 (de) 2010-11-15
PT1994410E (pt) 2011-01-10
JP2009525041A (ja) 2009-07-09
US20100062450A1 (en) 2010-03-11
DK1994410T3 (da) 2011-01-31
DE602007010108D1 (https=) 2010-12-09
PL1994410T3 (pl) 2011-12-30
JP5091163B2 (ja) 2012-12-05
IL193097A (en) 2013-03-24
US9394569B2 (en) 2016-07-19
WO2007088537A3 (en) 2007-10-25
EP1994410A2 (en) 2008-11-26
IL193097A0 (en) 2009-02-11
ES2355388T3 (es) 2011-03-25
EP1994410B1 (en) 2010-10-27
WO2007088537A2 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
PL1994410T3 (pl) Sposoby wczesnego wykrywania raka
WO2007089911A3 (en) Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
BRPI0607508A2 (pt) métodos e ácidos nucléicos para análise de distúrbios proliferativos celulares
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
TW200643175A (en) Markers for prenatal diagnosis and monitoring
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
WO2006085984A3 (en) Immune cell biosensors and methods of using same
FI20050011A7 (fi) Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi
WO2012174282A3 (en) Biomarker compositions and methods
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2013134786A3 (en) Biomarker compositions and methods
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2006076025A3 (en) Immune cell biosensors and methods of using same
WO2008140463A3 (en) Biomarker panels for assessing radiation injury and exposure
EP2186912A3 (en) Materials and methods for assaying for methylation of CpG islands associated with genes in the evaluation of cancer
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2006015383A3 (en) Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2010020619A3 (en) Susceptibility to dasatinib
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
TW200510546A (en) Methods of determining a chemotherapeutic regimen based on loss of heterozygosity at the thymidylate synthase locus